The Foundation funded preclinical studies for the approach and launched Opus.

Greta Streimikyte, a blind para-athletic running champion from Ireland, talks to host Ben Shaberman about growing up with substantial vision loss from retinopathy of prematurity and her competitive running career. Greta has won gold in the women's 1500 meters at the 2018 and 2021 European Para Athletic Championships and is a three-time Paralympian.

October 31, 2025. Dr. Victoria Claire has commissioned more than 200 sculptures, received an honorary doctorate, and is pursuing a PhD. She talks with host Ben Shaberman about her journey with retinitis pigmentosa, and how blindness has provided her with new and profound insights into herself and perceiving the world. Visitors to her current exhibition, "The Sense of Sculpture" (Oct. 18 - Nov. 1) at The Art House in Wakefield, England, are interacting with her sculptures tactilely in complete darkness.

The approach may provide better visual acuity than current optogenetic therapies in clinical trials.

October 17, 2025. Sam Seavey, founder and host of the acclaimed The Blind Life YouTube channel, talks with host Ben Shaberman about his journey with Stargardt disease, some of the latest assistive technologies, and how the 900+ videos on The Blind Life can be informative and helpful for people with low vision.

The emerging therapy improved vision for some participants in an earlier clinical trial.

Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.

Lance Baldo, MD, CEO at Beacon Therapeutics, talks to host Ben Shaberman about his company's fully enrolled Phase 3 VISTA clinical trial for laru-zova, a gene therapy for X-linked retinitis pigmentosa (RPGR mutations) that's showed promising results in earlier trials. They also discuss Beacon's forthcoming clinical trial for its dry age-related macular degeneration gene therapy.

The documentary “Aggie: An Incredible Story of Art and Justice” chronicles her story.

NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.